147 related articles for article (PubMed ID: 24756783)
1. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2014; 201():1-25. PubMed ID: 24756783
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
[TBL] [Abstract][Full Text] [Related]
3. Imatinib Mesylate.
Waller CF
Recent Results Cancer Res; 2018; 212():1-27. PubMed ID: 30069623
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
Nadal E; Olavarria E
Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
[TBL] [Abstract][Full Text] [Related]
5. The biology of signal transduction inhibition: basic science to novel therapies.
Griffin J
Semin Oncol; 2001 Oct; 28(5 Suppl 17):3-8. PubMed ID: 11740801
[TBL] [Abstract][Full Text] [Related]
6. Indications for imatinib mesylate therapy and clinical management.
Guilhot F
Oncologist; 2004; 9(3):271-81. PubMed ID: 15169982
[TBL] [Abstract][Full Text] [Related]
7. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
8. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
9. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
10. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
11. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
[TBL] [Abstract][Full Text] [Related]
12. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Dziba JM; Ain KB
J Clin Endocrinol Metab; 2004 May; 89(5):2127-35. PubMed ID: 15126530
[TBL] [Abstract][Full Text] [Related]
14. [Hematological side effects of tyrosine kinase inhibition using imatinib].
Schmitt-Graeff A; Hochhaus A
Pathologe; 2006 Feb; 27(1):40-6. PubMed ID: 16421705
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
16. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
18. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
19. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
20. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.
Cang S; Liu D
J Hematol Oncol; 2008 Oct; 1():15. PubMed ID: 18828913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]